Natera Plans to Commercialize Tumor Whole Exome Sequencing from Plasma - Onco'Zine
Natera, a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease, plans to commercialize a research-use-only service for whole exome sequencing of circulating tumor DNA, using plasma samples from patients with cancer.